333 related articles for article (PubMed ID: 37318607)
1. Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2.
Shehzadi K; Saba A; Yu M; Liang J
Top Curr Chem (Cham); 2023 Jun; 381(5):22. PubMed ID: 37318607
[TBL] [Abstract][Full Text] [Related]
2. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
[TBL] [Abstract][Full Text] [Related]
3. Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.
Bai X; Sun H; Wu S; Li Y; Wang L; Hong B
Front Immunol; 2022; 13():844749. PubMed ID: 35464436
[TBL] [Abstract][Full Text] [Related]
4. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
[TBL] [Abstract][Full Text] [Related]
5. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target.
Wang Y; Anirudhan V; Du R; Cui Q; Rong L
J Med Virol; 2021 Jan; 93(1):300-310. PubMed ID: 32633831
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
Shannon A; Le NT; Selisko B; Eydoux C; Alvarez K; Guillemot JC; Decroly E; Peersen O; Ferron F; Canard B
Antiviral Res; 2020 Jun; 178():104793. PubMed ID: 32283108
[TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 RNA dependent RNA polymerase inhibitors using pharmacophore modelling, molecular docking and molecular dynamics simulation approaches.
Pundir H; Joshi T; Pant M; Bhat S; Pandey J; Chandra S; Tamta S
J Biomol Struct Dyn; 2022; 40(24):13366-13377. PubMed ID: 34637693
[TBL] [Abstract][Full Text] [Related]
8. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
Elfiky AA
Life Sci; 2020 Jul; 253():117592. PubMed ID: 32222463
[TBL] [Abstract][Full Text] [Related]
9. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against
Naidu SAG; Mustafa G; Clemens RA; Naidu AS
J Diet Suppl; 2023; 20(2):254-283. PubMed ID: 34850656
[TBL] [Abstract][Full Text] [Related]
10. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
[TBL] [Abstract][Full Text] [Related]
11. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
12. A computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
Ribaudo G; Ongaro A; Oselladore E; Zagotto G; Memo M; Gianoncelli A
J Biomol Struct Dyn; 2022 Feb; 40(3):1101-1108. PubMed ID: 32948103
[TBL] [Abstract][Full Text] [Related]
13. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
Chien M; Anderson TK; Jockusch S; Tao C; Li X; Kumar S; Russo JJ; Kirchdoerfer RN; Ju J
J Proteome Res; 2020 Nov; 19(11):4690-4697. PubMed ID: 32692185
[TBL] [Abstract][Full Text] [Related]
14. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
Zhao J; Zhang G; Zhang Y; Yi D; Li Q; Ma L; Guo S; Li X; Guo F; Lin R; Luu G; Liu Z; Wang Y; Cen S
Antiviral Res; 2021 Dec; 196():105209. PubMed ID: 34801588
[TBL] [Abstract][Full Text] [Related]
15. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.
Lung J; Lin YS; Yang YH; Chou YL; Shu LH; Cheng YC; Liu HT; Wu CY
J Med Virol; 2020 Jun; 92(6):693-697. PubMed ID: 32167173
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors.
Brindani N; Munafò F; Menichetti A; Donati E; Nigro M; Ottonello G; Armirotti A; De Vivo M
Bioorg Med Chem; 2023 Feb; 80():117179. PubMed ID: 36716583
[TBL] [Abstract][Full Text] [Related]
17. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase.
Bertolin AP; Weissmann F; Zeng J; Posse V; Milligan JC; Canal B; Ulferts R; Wu M; Drury LS; Howell M; Beale R; Diffley JFX
Biochem J; 2021 Jul; 478(13):2425-2443. PubMed ID: 34198323
[TBL] [Abstract][Full Text] [Related]
18. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
Rabie AM
Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
Mishra A; Rathore AS
Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060
[TBL] [Abstract][Full Text] [Related]
20. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]